Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes
- 15 January 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 105 (2) , 526-532
- https://doi.org/10.1182/blood-2004-03-1106
Abstract
Markers of inflammation (eg, interleukin-6 [IL-6]), and endothelial perturbation (von Willebrand factor [VWF], circulating endothelial cells [CECs]) are altered in acute coronary syndromes (ACS). We hypothesized that CECs and IL-6 levels during the first 48 hours of ACS would predict 30-day and 1-year major cardiovascular end points (MACE). A total of 156 patients with ACS were included. Blood was drawn on admission (baseline) and 48 hours later for plasma VWF, IL-6 (both enzyme-linked immunosorbent assay [ELISA]), and CECs (CD146 immunomagnetic separation). CEC phenotyping was performed by indirect immunoperoxidase staining. At 30 days, 48 patients had a MACE, a predicted by baseline and 48-hour CECs and IL-6 levels, 48-hour VWF levels, and by the “admission–48 hour change” (Δ) in CECs, VWF, and IL-6 (all P = .002). On multivariate analysis, 48-hour CECs (P < .001) were the strongest predictor of MACE, followed by ΔIL-6 (P = .01) and ΔVWF (P = .048); 48-hour CECs were the only predictor of death (P = .007). At 1 year, 65 patients had MACE, predicted by 48-hour CECs and ΔIL-6 levels (P < .001); age (P = .046) and 48-hour CECs (P < .001) were the only predictors of death. CECs stained 93% positive for endothelial nitric oxide synthase (eNOS) but were less than 1% positive for CD34, CD36, and CD45 and less than 3% for CD31. Like raised VWF, abnormal CECs and IL-6 levels during the first 48 hours of ACS were strongly associated with 30-day MACE. CECs at 48 hours were the only independent predictor of both death and MACE at 30 days and 1 year, indicating the crucial role of endothelial/vascular damage in ACS pathophysiology.Keywords
This publication has 34 references indexed in Scilit:
- Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensityBlood, 2004
- Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cellsRelationship with von Willebrand factor and tissue factorPublished by Oxford University Press (OUP) ,2004
- A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertensionBlood Coagulation & Fibrinolysis, 2003
- Circulating endothelial cells in pulmonary hypertensionThrombosis and Haemostasis, 2003
- Immunophenotypic analysis of human spleen compartmentsAnnals of Anatomy - Anatomischer Anzeiger, 2002
- Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?Blood Coagulation & Fibrinolysis, 2000
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJournal of the American College of Cardiology, 2000
- Donor origin of circulating endothelial progenitors after allogeneic bone marrow transplantationTransplantation and Cellular Therapy, 2000
- Origins of circulating endothelial cells and endothelial outgrowth from bloodJournal of Clinical Investigation, 2000
- S‐Endo 1, a pan‐endothelial monoclonal antibody recognizing a novel human endothelial antigenTissue Antigens, 1996